

ITI VALUE FUND

An open ended equity scheme following a value investment strategy

NFO Period: 25th May- 8th June, 2021


UNLOCK^{THE}
HIDDEN **VALUE**




WHY EQUITY AS AN ASSET CLASS?



WHY EQUITY AS AN ASSET CLASS?




A COMPARISON ACROSS ASSET CLASSES



<http://www.nsiindia.gov.in/> - interest Rates taken as simple annual average from 2008 till 2021, SBI FD Rates – SBI Website , Gold Prices are LBMA AM Fixed and Nifty data – Source – Bloomberg and returns are in CAGR Past Performance may or may not be sustainable in future. Investments in mutual funds should not be construed as a guarantee of any minimum returns. There is no capital protection guarantee or assurance of any return. Kindly consult your financial advisor before investing.

EQUITIES HAVE OUTPERFORMED FIXED INCOME OVER LONG PERIODS OF TIME



*Data Period Apr 2000 to Mar 2021. Returns above 1Y are CAGR. Past Performance may or may not be sustainable in future. Investments in mutual funds should not be construed as a guarantee of any minimum returns. There is no capital protection guarantee or assurance of any return. Kindly consult your financial advisor before investing.

DIFFERENCE BETWEEN VOLATILITY AND RISK



VOLATILITY

Sharp movement in stock prices in the near term can be caused due to systemic events or sentiments surrounding the country, sector or the company itself.



RISK

Potential downside because of deterioration in fundamentals, business environment, management quality and sectoral dynamics resulting in loss of invested capital


Volatility is a friend of a smart investor and gives opportunities to buy at attractive price points

Befriending volatility and reducing the risk of loss of capital is key in Investing.

IS IT THE RIGHT TIME TO INVEST?



CURRENT ECONOMIC SCENARIO



“PRICE IS WHAT
YOU PAY;
VALUE IS WHAT
YOU GET.”

BEN GRAHAM

VALUE INVESTING WILL NEVER GO OUT OF STYLE. BECAUSE
VALUE INVESTING IS ALWAYS WANTING TO GET MORE VALUE
THAN YOU PAY FOR WHEN YOU BUY A STOCK. THAT
APPROACH WILL NEVER GO OUT OF STYLE.

I THINK ALL GOOD INVESTING IS VALUE INVESTING. IT'S
JUST THAT SOME PEOPLE LOOK FOR VALUES IN STRONG
COMPANIES AND SOME LOOK FOR VALUES IN WEAK
COMPANIES. EVERY VALUE INVESTOR TRIES TO GET MORE
VALUE THAN HE PAYS FOR.

- CHARLIE MUNGER

WHAT DO WE LOOK FOR IN VALUE INVESTING

**01 - Demonstrated
Consistent Earnings Power**

**05 - Trading at
Significant discount to
Intrinsic Value**


**02 - Good RoEs with
Little or no Debt**

**04 - Simple
Businesses**

**03 - Good
Management in place**



VALUE INVESTING UNIVERSE



INTRINSIC VALUE




KEY ASPECTS TO BE CONSIDERED IN VALUE INVESTING



MARGIN OF SAFETY

ONE OF THE PILLARS OF OUR INVESTING PHILOSOPHY



Margin of safety is a principle of investing in which an investor only purchases securities when their market price is significantly below their Intrinsic value

The difference between the Intrinsic value and the CMP denotes the margin of Safety. It acts as a downside cushion.

SQL is our Investment Philosophy wherein
S – Margin of Safety is an important consideration
in its investment decision making process

PRESENTING ITI VALUE FUND




WHY INVEST IN VALUE FUND?



MARKETS ARE OFTEN DRIVEN BY SENTIMENTS OF GREED & FEAR


"Be fearful when everyone is greedy, be greedy when everyone is fearful"

- Warren Buffett




*Data Period Dec 2003 to Apr 2021. Returns above 1Y are CAGR. Past Performance may or may not be sustainable in future. Investments in mutual funds should not be construed as a guarantee of any minimum returns. There is no capital protection guarantee or assurance of any return. Kindly consult your financial advisor before investing.

DURING SUCH PERIODS, DIFFERENT SEGMENTS WITHIN MARKETS REACT DIFFERENTLY



Data Period Dec 2003 to Apr 2021. Returns above 1Y are CAGR. Past Performance may or may not be sustainable in future. Investments in mutual funds should not be construed as a guarantee of any minimum returns. There is no capital protection guarantee or assurance of any return. Kindly consult your financial advisor before investing.

AND THEREIN LIE THE OPPORTUNITIES...




- Prices move based on sentiments or events resulting in price distortions
- Either entire sector / sub sector can be subjected to these price impacts or it may be specific to a company
- Such Distortions may result in providing opportunities to Value Investors to evaluate such Stocks / sectors

CASE STUDY 1 - NESTLE

SECTOR - CONSUMER

- The company is a leading consumer goods company. It faced state FDA sanctions on a key product in 2QCY15 due to which its stock price corrected ~30% in a 9 month period.
- The company in the preceding 2 years had an average RoCE of >50%, which fell to <30% in CY15. Earnings CAGR over CY14-16 was - 7.3%.
- Subsequent to the crisis being resolved, the company over CY16-20 reported 19.8% profit CAGR as compared to 9.8% CAGR over CY10-20. **It outperformed the NSE 100 index by >50% from the low in Feb'16 to May'21. Valuations expanded from a PE ~46x in Feb'16 (preceding 2 year average was ~55x) to ~71x in Feb'20; its past 3 year average PE is ~60x.**




10 year CAGR - CY10-20	%
Market capitalisation	17.1
Diluted EPS	9.8
ROE - FY21	105.8

Source: Bloomberg, AceEquity. Past performance may or may not be sustained in the future. Sector(s) / Stock(s)/Issuers(s) mentioned above are for the purpose of illustration and should not be construed as recommendation. The fund manager(s) may or may not choose to hold the stock mentioned from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s). Relative performance data from 1 April 2010 to 11 May 2021. Diluted EPS CAGR and market capitalisation CAGR from FY11 to FY21.

CASE STUDY 2 - IPCA LABS

SECTOR - PHARMACEUTICALS

- IPCA Labs is a vertically integrated generic pharma company that produces branded & generic formulations, APIs and Intermediates. It faced USFDA sanctions (import alert) on three of its units in Q4FY15 followed by disqualification by the Global Fund in April'16. This was a major setback as peak revenue from Global Fund's tender was USD 70mn in FY14. In June'17, USFDA also withdrew exemptions given to certain APIs and Formulations from import alert. Due to this unforeseen events between Q4FY15-Q1FY17, stock price corrected ~47%.
- The company in the preceding 2 years had an average RoCE of >26%, which fell to <5% in FY16. Earnings CAGR over FY14-16 was -55.9%.
- Subsequent to the approval from Global Fund for tender participation in Q1FY18, the company over FY16-20 reported 59.6% profit CAGR as compared to 11.3% CAGR over FY10-20. It outperformed the NIFTY MIDCAP 100 index by >275% from the low in Aug'17 to May'21. Valuations expanded from a PE ~27x to ~30x in Nov'20.



10 year CAGR - FY10-20	%
Market capitalisation	17.9
Diluted EPS	11.3
ROE - FY20	18.1

Source: Bloomberg, AceEquity. Past performance may or may not be sustained in the future. Sector(s) / Stock(s)/Issuers(s) mentioned above are for the purpose of illustration and should not be construed as recommendation. The fund manager(s) may or may not choose to hold the stock mentioned from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s). Relative performance data from 1 April 2010 to 11 May 2021. Diluted EPS CAGR and market capitalisation CAGR from FY11 to FY21.


CASE STUDY 3 - INFOSYS

SECTOR - IT

Infosys is a pioneer Indian multinational IT company. From **FY05 to FY15**, its **revenues had compounded at 22% CAGR**, while its **earnings grew at 21% CAGR**.

Over FY15-17, growth decelerated with revenues growing at 13%, and earnings growth slowing down to 8% CAGR. Market Cap during this period declined by -4% CAGR.

With the **announcement of Vishal Sikka's (CEO) resignation in Aug'17**, stock plunged to a 3yr low on concerns of uncertainty. Its TTM PE Multiple contracted to ~14x (vs. 5yr avg. PE of 19x), despite **strong ROCE & ROEs of 29% & 23% respectively & a healthy Free Cash to PAT conversion of ~75%+**.




- Subsequent to this period with announcement of a new CEO in Dec'19 & laying down of strategic growth roadmap PE discount of Infosys, relative to Nifty reduced from a peak of ~40% in Aug'17 to ~15% in Mar'19.
- Resultantly, Infosys outperformed Nifty by ~2100bps over FY17-FY19.

Source: Bloomberg, AceEquity. Past performance may or may not be sustained in the future. Sector(s) / Stock(s)/Issuers(s) mentioned above are for the purpose of illustration and should not be construed as recommendation. The fund manager(s) may or may not choose to hold the stock mentioned from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s). Relative performance data from 1 April 2010 to 11 May 2021. Diluted EPS CAGR and market capitalisation CAGR from FY11 to FY21.

CASE STUDY 4 - PHARMA SECTOR

- After hitting high in April'15, NIFTY Pharma Index was continuously under pressure till Oct'19 where the index was trading way below its 10-year average PE of 30.1x and corrected by 48.3% over April'15 to Oct'19. NIFTY Pharma Index underperformed NIFTY50 Index by 76% over April'15 to Oct'19
- Reason for underperformance was earnings pressure on account of : a) significant pricing pressure in US market for generics led by distributors consolidation, b) increase in frequency of USFDA plant audits, c) high competitive intensity due to increase in ANDA approvals by USFDA, and d) increase in leverage as few companies went for M&A opportunities
- Leading Indian pharma companies emerged stronger and have used that downcycle to reallocate capital and strengthen R&D capabilities by focusing on better quality ANDA filings , improving USFDA compliance and strengthening of balance sheet. **Between October 2019 till April 2021, NSE Pharma Index outperformed Nifty by 60%.**




NIFTY Pharma Index	CY15	CY19	CY20
RoE (%)	17.1	9.7	13.4
Net debt / EBITDA (x)	0.2	2.3	0.3
PE (x)	33.5	22.8	33.5
EV / EBITDA (x)	21.0	13.1	19.9
PB (x)	6.1	2.5	4.8

Source: Bloomberg, AceEquity. Past performance may or may not be sustained in the future. Sector(s) / Stock(s)/Issuers(s) mentioned above are for the purpose of illustration and should not be construed as recommendation. The fund manager(s) may or may not choose to hold the stock mentioned from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s). Relative performance data from 1 April 2010 to 11 May 2021. Diluted EPS CAGR and market capitalisation CAGR from FY11 to FY21.

CASE STUDY 5 - BUILDING MATERIALS

INDUSTRY - CERAMICS INDUSTRY

- Ceramic players such as Kajaria, Somany and Cera Sanitaryware have developed themselves as a brand. Till around 2010-11, brand value in ceramics was not understood well and these were treated as commoditised sector.
- All the above 3 companies were performing consistently at a EPS CAGR of 40% during 2009-13 and decent return ratios.
- It was by about late 2011-12, market started recognising consistent performance, long term growth potential and brand value of these companies, resulting in smart outperformance.



FY 10-13 (CAGR growth in %)	Kajaria	Cera	Somany
Market capitalisation	44%	54%	31%
Adjusted EPS	31%	24%	12%
Pre and Post 2010 Returns			
Avg RoE Pre 2010	11.75	21.87	8.02
Avg RoE 2010-2013	29.91	26.53	24.61
Avg RoCE Pre 2010	12.91	23.80	12.01
Avg RoCE 2010-2013	27.08	32.25	20.40

Source: Bloomberg, AceEquity. Past performance may or may not be sustained in the future. Sector(s) / Stock(s)/Issuers(s) mentioned above are for the purpose of illustration and should not be construed as recommendation. The fund manager(s) may or may not choose to hold the stock mentioned from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s). Relative performance data from 1 April 2010 to 11 May 2021. Diluted EPS CAGR and market capitalisation CAGR from FY11 to FY21.

CASE STUDY 6 - MID & SMALL CAP IT

- FY16-19 was an unique phase where the **poster boys of the Indian IT sector**, saw their growth slowing down and increased investments in digital transformational initiatives impacting their margins. **FY16-19, their combined PAT grew at just 7% CAGR. Consequently they underperformed the Nifty 50 Index by ~400bps over the same period.**
- On the contrary, **niche mid & small cap IT names were growing with improving profitability metrics with their PAT up by 15% CAGR.** This was coupled with strong free cash conversion (FCF/PAT of ~90%+), strong 26% CAGR in free cash generation & improving return ratios. Despite this in FY16 they were trading at ~25% discount to Nifty Midcap TTM PE of 25 providing a value opportunity.

** Aggregate of TCS, Infosys, Wipro & Tech Mahindra*

Large Caps *	Implied TTM PE	Nifty 50 Index	MCap (Rs crs)	Revenues (Rs crs)	EBIT Margins %	PAT (Rs crs)	Free Cash (Rs crs)	FCF/PAT	ROE % (derived)	Avg. Div. Pay-out (%)
Mar-16	19.3	7,738	9,55,847	2,48,825	23.0%	49,604	39,046	79%	25.2	28
Mar-17	16.9	9,174	8,78,474	2,70,631	21.9%	51,944	49,190	95%	22.9	28
Mar-18	18.2	10,114	9,74,988	2,78,886	21.4%	53,663	49,233	92%	24.3	34
Mar-19	21.5	11,624	12,96,214	3,22,465	22.1%	60,177	58,165	97%	25.6	33
CAGR (16-19)		15%	11%	9%		7%	14%			

Aggregate of Mindtree, Tata Elxsi, NIIT Tech, Persistent & Mphasis

Mid & Smallcaps #	Implied TTM PE	Nifty Midcap Index	MCap (Rs crs)	Revenues (Rs crs)	EBIT Margins %	PAT (Rs crs)	Free Cash (Rs crs)	FCF/PAT	ROE % (derived)	Avg. Div. Pay-out (%)
Mar-16	19.1	12,753	36,300	16,824	13.8%	1,897	1,335	70%	15.8	38
Mar-17	16.4	17,197	31,813	18,231	12.9%	1,934	2,013	104%	15.0	34
Mar-18	20.4	18,757	45,849	19,420	13.2%	2,251	2,227	99%	17.5	32
Mar-19	18.5	18,259	53,137	23,392	14.8%	2,872	2,647	92%	20.6	24
CAGR (16-19)		13%	14%	12%		15%	26%			

Source: Bloomberg, AceEquity. Past performance may or may not be sustained in the future. Sector(s) / Stock(s)/Issuers(s) mentioned above are for the purpose of illustration and should not be construed as recommendation. The fund manager(s) may or may not choose to hold the stock mentioned from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s). Relative performance data from 1 April 2010 to 11 May 2021. Diluted EPS CAGR and market capitalisation CAGR from FY11 to FY21.

WHY ITI VALUE FUND?





ALL INTELLIGENT INVESTING IS VALUE INVESTING

- ACQUIRING MORE THAN YOU ARE PAYING
FOR. YOU MUST VALUE THE BUSINESS IN
ORDER TO VALUE THE STOCK. ”

CHARLIE MUNGER

PRODUCT FEATURES

Top down Sector allocations based on macro drivers



Better payoffs upon Price Normalization



Strong bottom up stock selection focussing on Price Value Gap



Ideal investment Horizon of 3 – 5 years



Stock level limits –
7% - Large Caps,
5% - Mid Caps,
3% - Small Caps
at the time of purchase



Value Investing Strategy across Market Caps



The Portfolio may retain Cash from time to time depending upon the availability of Value opportunities

PRODUCT ADVANTAGES

Value Picking Opportunities



PRODUCT ADVANTAGES/BENEFITS



The Portfolio may retain Cash from time to time depending upon the availability of Value opportunities

WHO SHOULD INVEST?



MEET THE FUND MANAGERS AND UNDERSTAND THEIR LEARNINGS



Mr. Pradeep Gokhale

Head - Equity



Mr. Rohan Korde

Fund Manager

The more irrational the market's behaviour, the greater the opportunity for the disciplined investor.

Never overpaying for an investment and buying with margin of safety can minimize your downside.

Contrarian thinking is part of value investing. A stock becomes more risky as its price rises

But the company's underlying business must be solid and its share price must be reasonable.

2 principal reasons why the wider market will undervalue a stock: currently disappointing results and protracted neglect or unpopularity.

Undervalued investments provide significant upside in the long run.


Value investing needs a sound intellectual framework for making decisions and the ability to prevent emotions from corroding that framework

The higher the price you pay today, the lower your return will be tomorrow.

PORTFOLIO STRATEGY- VALUE INVESTING



OUR EQUITY INVESTMENT PROCESS



OUR INVESTMENT APPROACH & RISK MANAGEMENT

Diligent Screening and Evaluation

Disciplined approach towards screening and evaluation of stocks eligible under a stated investment mandate with comprehensive Research

Experienced Personnel

Dedicated and knowledgeable team of Analysts promptly mentored by senior experienced Investment Professionals

Continuous Monitoring


Post investment Decision, the investee companies are always under the radar for monitoring their valuation metrics, company fundamentals and any news surrounding the same

Internal Limits

Robust internal risk management framework to avoid any instances of undue concentration risks and higher volatility

Periodic Position Sizing

Regular evaluation of Portfolio sizing to optimize the risk reward trade-off and simultaneously ensuring conformance with stated investment mandate



OUR EQUITY INVESTMENT PHILOSOPHY



The above philosophy seeks to generate long term wealth for our investors.

INVESTMENT STYLE IS 'GARP' Growth At Reasonable Prices



WHAT WILL BE THE INVESTMENT?



WHAT DO WE LOOK FOR?

Great companies going through temporary tough times and trading at prices significantly below their intrinsic value

Stocks where deleveraging and improvement in RoEs / Cash Flows visible

Companies within Sectors facing Macro headwinds and can reverse

Emerging Sectors with growth potential available at significant value

Companies going through Business / Management Restructuring

Cyclical stocks trading at bottom of the business cycle

Good Sectors trading at attractive valuations because of near term growth headwinds

Fund may continue to retain the stock in the portfolio as long as fundamentals are intact and valuation is reasonable

INVESTMENT TEAM

GEORGE HEBER JOSEPH
CEO & CIO

Pradeep Gokhale
Head - Equity

Vikrant Mehta
Head – Fixed
Income

C.Balasubramanian
Compliance &
Risk Management

Dealing Team - Debt

**Dealing Team
-Equity**

Madhur Maheshwari Quant
Strategist B.Tech IIT Mumbai

Fund Manager / Research Analysts

Shashank Sawant
Dealer

Priya Sridhar
Senior Dealer

**Strategy, Modeling &
Quantitative Research**

Rohan Korde | Fund Manager
B. Com., MMS (Finance) | Experience 16
years FMCG, Consumer Durables, Auto

Sahil Doshi | Research Analyst | B Com, CFA,
CFP | Experience 10 years Retail, Food and
Beverages, Non-Lending Financials Media,
Telecom, Services and Textiles

Pratibh Agarwal | Sr. Research Analyst
M. Tech. (IIT, Kanpur) | Experience 11
Years | Industrials, Construction, Real
Estate, Power, Transportation

Hetal Gada | Research Analyst B Com.
PGDM (Fin) | Experience 6 years Cement,
Metals and Oil & Gas

Bhavesh Jain | Research Analyst BE, MBA
in Finance | Experience 12 Years | Pharma
& Healthcare, Agri & Chemicals

Ayushi Garodia | Research Analyst B. Com.
Chartered Accountant | Experience 4 years
Banking and Financial Services

Shweta Raut
Dealer

Vikas Nathani
Dealer

Research and Fund Management Team with a combined experience of 114 years across sectors


ITI VALUE FUND

(An open-ended equity following Value Investing Strategy)

NFO Opens: 25th May 2021

NFO Closes: 8th June 2021

Available on BSE StAR MF, NSE-MFSS, NSE NMF II and MFU platforms.

 1800 266 9603

 mfassist@itiorg.com

 www.itiame.com

ITI VALUE FUND



Benchmark - Nifty 500 Value 50 TRI

Investment Objective- The investment objective of the scheme is to seek to generate long term capital appreciation by investing substantially in a portfolio of equity and equity related instruments by following value investing strategy. However, there can be no assurance that the investment objective of the scheme would be achieved.

Type of Instruments	Indicative Allocation (% Of Total Assets)		Risk Profile
	Maximum	Minimum	High/Medium/Low
Equity and Equity related instruments	100%	65%	High
Preference Shares	10%	0%	Medium to High
Debt and Money Market Instruments	35%	0%	Low to Medium
Units issued by REITs and InvITs	10%	0%	Medium to High

Fund Managers - Mr. Pradeep Gokhale and Mr. Rohan Korde

Minimum Investment Amount - Rs. 5000 and in multiples of Rs. 1 thereafter

Minimum Additional Investment Amount - Rs. 1000 and in multiples of Rs. 1 thereafter

Plans & Options - Plans - Direct & Regular Plan. Options – Growth & IDCW

Exit Load - 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units; Nil thereafter.

RISKOMETER & DISCLAIMERS

www.itiamc.com

Toll Free Number 1800 266 9603 | Email mfassist@itiorg.com

All figures and data given in the document are dated unless stated otherwise. In the preparation of the material contained in this document, the AMC has used information that is publicly available, including information developed in-house. However, the AMC does not warrant the accuracy, reasonableness and/ or completeness of any information.

The information provided is not intended to be used by investors as the sole basis for investment decisions, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific investor. Investors are advised to consult their own legal tax and financial advisors to determine possible tax, legal and other financial implication or consequence of subscribing to the units of ITI Mutual Fund. The information contained herein should not be construed as a forecast or promise nor should it be considered as an investment advice.

The AMC (including its affiliates), the Mutual Fund, the trust and any of its officers, directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner

Mutual Fund investments are subject to market risks, read all scheme related documents carefully

This product is suitable for investors who are seeking*

- Capital appreciation over the long term
- Investment in portfolio predominantly consisting of equity and equity related instruments of mid cap companies

***Investors should consult their financial advisors if in doubt about whether the product is suitable for them.**





THANK YOU!